Core Viewpoint - The articles promote the Growth Stock Forum as a platform for identifying and tracking growth stocks, particularly in the biotech sector, emphasizing attractive risk/reward situations for investors [1][2]. Group 1: Growth Stock Forum Features - The forum includes a model portfolio consisting of 15-20 stocks that are updated regularly [2]. - A top picks list is provided, featuring up to 10 stocks anticipated to perform well in the current calendar year [2]. - The forum offers trading ideas aimed at both short-term and medium-term market movements [2]. Group 2: Analyst's Position - The analyst has a beneficial long position in GMAB shares, indicating a personal investment interest [3]. - The article reflects the author's opinions and is not compensated by any company mentioned, ensuring an independent perspective [3].

Market Overview - U.S. stocks exhibited mixed performance, with the Nasdaq Composite increasing by over 100 points on Monday [1] - Cannabis-linked stocks experienced significant gains following President Trump's video promoting the health benefits of cannabis [1] Company Highlights - Tilray Brands, Inc. (NASDAQ: TLRY) saw a sharp increase in shares, rising 39.2% to $1.5983 [1] - Merus N.V. (NASDAQ: MRUS) gained 36.6% to $94.14 after Genmab agreed to acquire the company for $97 per share [4] - Better Home & Finance Holding Company (NASDAQ: BETR) increased by 20.1% to $63.60, supported by a $75 million at-the-market offering for Class A shares [4] - BTQ Technologies Corp. (NASDAQ: BTQ) jumped 20% to $6.36, as Danal began proof-of-concept for BTQ's quantum-secure Stablecoin settlement network [4] - SNDL Inc. (NASDAQ: SNDL) rose 18.8% to $2.77, benefiting from the positive sentiment around cannabis stocks [4] - Innoviz Technologies Ltd. (NASDAQ: INVZ) increased by 15.6% to $1.9701 after Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $1.50 to $2.50 [4] - Sandisk Corporation (NASDAQ: SNDK) shares jumped 14.3% to $111.06 [4] - GDEV Inc. (NASDAQ: GDEV) rose 12.7% to $29.24 [4] - Ondas Holdings Inc. (NASDAQ: ONDS) gained 12.2% to $8.59 [4] - Pony AI Inc. (NASDAQ: PONY) increased by 10.3% to $23.36, with Citigroup initiating coverage with a Buy rating and a price target of $29 [4] - Galaxy Digital (NASDAQ: GLXY) gained 9.5% to $33.85 [4] - Western Digital Corporation (NASDAQ: WDC) rose 9% to $116.48 after Rosenblatt raised its price target from $90 to $125 while maintaining a Buy rating [4] - New Oriental Education & Technology Group Inc. (NYSE: EDU) increased by 5% to $53.85, with B of A Securities maintaining a Buy rating and raising the price target from $56.2 to $58.2 [4] - GLOBALFOUNDRIES Inc. (NASDAQ: GFS) rose 5% to $37.40 following a collaboration announcement with Corning for developing detachable fiber connector solutions [4]

Core Viewpoint - Genmab A/S has agreed to acquire Merus N.V. for $97 per share in an all-cash transaction valued at approximately $8 billion, expected to close by early Q1 2026 [1][2]. Group 1: Acquisition Details - The acquisition is aimed at accelerating Genmab's transition to a wholly owned model, expanding and diversifying its revenue streams for sustained growth into the next decade [2]. - The purchase price of $97.00 per share represents a 41% premium over Merus' closing stock price of $68.89 on September 26, 2025, and a 44% premium over its 30-day volume weighted average price of $67.42 [6]. Group 2: Strategic Fit and Pipeline - Adding petosemtamab, Merus' lead asset, aligns with Genmab's expertise in antibody therapy development and commercialization in oncology, enhancing its late-stage pipeline [3][4]. - Following the acquisition, Genmab will have four proprietary programs expected to lead to multiple new drug launches by 2027 [3]. Group 3: Product Potential - Petosemtamab is an EGFRxLGR5 bispecific antibody with potential first- and best-in-class status in head and neck cancer, showing significantly higher overall response rates and median progression-free survival compared to standard care [4]. - Genmab anticipates the initial launch of petosemtamab in 2027, with plans to broaden its development into earlier lines of therapy [5]. Group 4: Financial Projections - Genmab expects petosemtamab to be accretive to EBITDA, with an estimated annual sales potential of at least $1 billion by 2029, and multi-billion-dollar annual revenue potential thereafter [6]. - The deal is viewed positively by analysts, as it adds an asset with peak sales potential of $3 billion to $4 billion in head and neck cancer alone [7][8].

Group 1 - Genmab announced its plan to acquire Merus for approximately $8 billion, significantly boosting Merus's stock price by over 37% [1][3] - Merus is developing petosemtamab, a drug that targets head-and-neck cancer and metastatic colorectal cancer, with potential peak sales estimated between $3 billion to $4 billion for head-and-neck cancer alone [2] - The acquisition is viewed positively as it enhances Genmab's portfolio with late-stage programs that could lead to substantial revenue growth in the 2030s, surpassing previous revenue peaks from Darzalex royalties [2] Group 2 - The deal values Merus at a 41% premium compared to its closing price prior to the announcement, while Genmab's stock experienced a decline of nearly 3% [3] - Analysts have noted that the acquisition is larger than expected, indicating a strategic move by Genmab to strengthen its market position [2][6]

Market Overview - US equity futures are up sharply, led by tech and small caps, with the S&P 500 on track for its best September since at least 2013, despite the month typically being difficult for stocks [1] - Gold prices have reached a record high of $3,820, pushing the market value of US gold reserves above $1 trillion [9] - A potential US government shutdown could complicate a heavy data week, impacting labor market data releases [1][3] Company-Specific Developments - Mag 7 stocks are mostly higher in premarket trading, with notable gains for Amazon (+1%), Alphabet (+0.8%), and Nvidia (+0.8%) [3] - Genmab's acquisition of Merus for $8 billion has led to a 37% surge in Merus shares [5] - Occidental Petroleum is in talks to sell its OxyChem petrochemical unit for at least $10 billion, resulting in a 1.5% gain in its shares [5] - MoonLake Immunotherapeutics shares plummeted 88% following disappointing clinical trial results [5] - Tilray shares rose 16% after President Trump promoted the medical benefits of hemp-derived CBD [5] Economic Indicators - The US economy is expected to add 50,000 jobs in September, with the unemployment rate projected to remain steady at 4.3% [4] - The JOLTS report is anticipated to show a decline in job openings, while company hiring data is likely to confirm a slowdown [4] - Fed policymakers are scheduled to speak throughout the week, influencing market expectations regarding interest rates [4][3] Global Market Trends - Global stocks are expected to continue their rally through year-end, supported by a resilient US economy and a dovish Fed stance [5][6] - European stocks are experiencing gains, with the Stoxx 600 climbing 0.4%, driven by optimism around economic growth and AI advancements [7] - Asian equities are mostly advancing, particularly Chinese tech stocks, with the Hang Seng index climbing for the first time in three sessions [8] Commodity Market Insights - WTI crude futures are trading around $65.30 amid expectations of OPEC+ output hikes, while precious metals continue their upward trend [1][13] - The Bloomberg Dollar Spot Index has fallen 0.2% as fears of a government shutdown emerge, impacting currency valuations [12]

Core Viewpoint - Genmab A/S has announced a cash acquisition of Merus NV for $97.00 per share, valuing the transaction at approximately $8 billion, which is expected to accelerate Genmab's transition to a fully integrated model and enhance its revenue sources [1][2]. Group 1: Transaction Details - The acquisition will be conducted in cash, with a total transaction value of about $8 billion [1]. - The deal has received unanimous approval from the boards of both companies [2]. - Genmab's wholly-owned subsidiary will initiate a tender offer for 100% of Merus's common stock, anticipated to be completed in early Q1 2026 [2]. Group 2: Financial Aspects - The acquisition price of $97.00 per share represents a premium of approximately 41% over Merus's closing price of $68.89 on September 26, 2025 [2]. - The offer also reflects a premium of about 44% compared to Merus's 30-day volume-weighted average price of $67.42 [2]. Group 3: Strategic Implications - Acquiring Merus is expected to significantly accelerate Genmab's transition to a fully integrated model [2]. - The acquisition aims to expand and enrich Genmab's revenue sources, driving sustained growth over the next decade [2]. - This move positions Genmab to become a leader in the biotechnology sector [2].

Core Viewpoint - Merus has agreed to be acquired at a 41% premium following a successful trial of a cancer drug [1] Company Summary - The acquisition reflects confidence in Merus's recent positive trial results for its cancer drug, which may enhance its market position and investor interest [1] Industry Summary - The deal highlights ongoing consolidation trends in the biopharmaceutical industry, particularly in the oncology sector, as companies seek to bolster their drug pipelines through strategic acquisitions [1]

Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]

格隆汇9月29日｜荷兰制药商Merus(MRUS.US)盘前暴涨超38%，现报95.29美元。此前丹麦生物技术公 司Genmab同意以每股97美元的价格全现金收购Merus，交易价值约为80亿美元。 ...

Core Viewpoint - Genmab A/S is set to acquire Merus N.V. for USD 97.00 per share in an all-cash transaction valued at approximately USD 8.0 billion, aiming to enhance its portfolio and accelerate growth in the biotechnology sector [2][3][6]. Transaction Details - The acquisition has been unanimously approved by the Boards of Directors of both companies [2]. - Genmab will commence a tender offer for 100% of Merus' common shares, expected to close by early Q1 2026 [2][7]. - The purchase price represents a premium of approximately 41% over Merus' closing stock price on September 26, 2025, and approximately 44% over its 30-day volume weighted average price [8]. Strategic Fit and Growth Potential - The acquisition is expected to significantly accelerate Genmab's transition to a wholly owned model, diversifying revenue and driving sustained growth into the next decade [3][4]. - Petosemtamab, Merus' lead asset, is in Phase 3 development and has received two Breakthrough Therapy Designations from the FDA, indicating its potential as a transformational therapy for head and neck cancer [4][5]. - Genmab anticipates the initial launch of petosemtamab in 2027, with projected annual sales potential exceeding USD 1 billion by 2029 [5]. Financing and Financial Outlook - The transaction will be funded through cash on hand and approximately USD 5.5 billion of non-convertible debt financing, with a commitment from Morgan Stanley Senior Funding, Inc. [9][10]. - The acquisition is expected to be accretive to EBITDA by the end of 2029 [6]. Company Background - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform the lives of patients with cancer and other serious diseases by 2030 [13][14]. - Merus specializes in developing bispecific and trispecific antibody therapeutics, known as Multiclonics, which have shown promising results in clinical studies [15].